Article
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
Molecular cancer therapeutics - 1 Apr 2008
Banerji Udai, Affolter Annette, Judson Ian, Marais Richard, Workman Paul
Abstract excerpt
Oncogenic BRAF and NRAS mutations are frequent in malignant melanoma. BRAF that is activated by the common V600E and other mutations, as well as by upstream NRAS mutations, has been shown to require the molecular chaperone heat shock protein 90 (HSP90) for stabilization and is depleted by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)]. Here, we explore the possible relationship between tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.